Syndax Pharmaceuticals, Inc. (SNDX)
- Previous Close
20.79 - Open
20.43 - Bid 20.56 x 100
- Ask 20.62 x 100
- Day's Range
20.13 - 20.80 - 52 Week Range
11.22 - 25.34 - Volume
558,575 - Avg. Volume
1,100,204 - Market Cap (intraday)
1.748B - Beta (5Y Monthly) 0.98
- PE Ratio (TTM)
-- - EPS (TTM)
-2.98 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
35.27
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
www.syndax.comRecent News: SNDX
Performance Overview: SNDX
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNDX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNDX
Valuation Measures
Market Cap
1.75B
Enterprise Value
1.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-5.60
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.89%
Return on Equity (ttm)
-40.99%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-209.36M
Diluted EPS (ttm)
-2.98
Balance Sheet and Cash Flow
Total Cash (mrq)
577.58M
Total Debt/Equity (mrq)
0.29%
Levered Free Cash Flow (ttm)
-82.37M